Potential for Larger Gene Panels to Increase the Number of Molecularly Matched Therapies in Patients with Advanced Solid Tumours By Ogkologos - April 22, 2025 524 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ProfiLER-02 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR FOCUS4: Learning from a landmark clinical trial April 25, 2023 Dress up that Salad! December 21, 2020 Por qué no voy a “superar” los efectos a largo plazo... July 20, 2021 Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and... December 7, 2022 Load more HOT NEWS Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes... Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient... FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
